Browse

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea

Cited 21 time in Web of Science Cited 22 time in Scopus
Authors
Shin, Hee Young; Kang, Hyoung Jin; Park, Eun Sil; Choi, Hyoung Soo; Ahn, Hyo Seop; Kim, Sun Young; Chung, Nak Gyun; Kim, Hack Ki; Kim, So Youn; Kook, Hoon; Hwang, Tai Ju; Lee, Kwang Chul; Lee, Sun Min; Lee, Kun Soo; Yoo, Keon Hee; Koo, Hong Hoe; Lee, Mee Jung; Seo, Jong Jin; Moon, Hyung Nam; Ghim, Thad; Lyu, Chuhl Joo; Lee, Won Sik; Choi, Yong Mook
Issue Date
2005-08-27
Publisher
Wiley-Blackwell
Citation
Pediatr Blood Cancer. 2006 Apr;46(4):439-45.
Keywords
AdolescentChildChild, PreschoolDrug Administration ScheduleFemaleHematologic Neoplasms/*complicationsHumansHyperuricemia/*complications/*drug therapyInfantInfant, NewbornKorea/epidemiologyMaleProspective StudiesRecombinant Proteins/administration & dosage/therapeutic useRenal DialysisTreatment OutcomeUrate Oxidase/administration & dosage/adverse effects/*therapeutic useUric Acid/blood
Abstract
BACKGROUND: Hyperuricemia accompanying tumor lysis syndrome is a serious complication in neoplasia with rapid proliferation and destruction. To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies. PROCEDURE: Rasburicase was administered at 0.2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route for hyperuricemia (uric acid > 7.5 mg/dl). The study period was 5 weeks and consisted of a baseline assessment within 48 hr before the administration of rasburicase, 3-5 days of assessment during treatment and a follow-up assessment at 4 weeks after its final administration. RESULTS: The uric acid endpoint (< or =7.0 mg/dl) was reached in 97.3% (36/37) of the patients and uric acid levels were significantly reduced in all patients (P < 0.001). Drug related toxicities were mild and reversible without any grade 4 or serious adverse event associated with rasburicase. CONCLUSION: This study confirms that rasburicase is a safe and effective agent for the treatment of hyperuricemia associated with hematologic malignancies in pediatric patients.
ISSN
1545-5009 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16123985

http://hdl.handle.net/10371/28902
DOI
https://doi.org/10.1002/pbc.20555
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pediatrics (소아과학전공)Journal Papers (저널논문_소아과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse